Drugs / oleoyl-estrone
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00449254 | Oct 2006 → ? | obesity disorder | Manhattan Pharmaceuticals | Unknown | No outcome recorded |
| Phase 2 | NCT00449202 | Jun 2006 → ? | obesity disorder | Manhattan Pharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | oleoyl-estrone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00449254 ↗ |
| Known as | MP-101 | “oleoyl-estrone (MP-101)” NCT00449254 ↗1“oleoyl-estrone (MP 101)” NCT00449202 ↗ |
| Route | Oral | “fixed-dose repeated oral dosing for 30 days” NCT00449254 ↗ |